FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380079314> ?p ?o ?g. }

• W4380079314 endingPage "686" @default.
• W4380079314 startingPage "686" @default.
• W4380079314 abstract "Background: Marginal zone lymphoma (MZL) is a distinct subgroup of non-Hodgkin’s lymphoma (NHL), which is typically characterized by an indolent clinical course and long survival duration. In Korea, MZL accounts for 21% of all B-cell lymphoma and is the second most frequent histologic subtype following diffuse large B-cell lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observations including clinical presentation, evaluation patters, treatment modality, results, and side effects. Methods: Histological newly diagnosed patients with MZL were eligible. We received official approval from each study site their local IRB. All patients gave written informed consent prior to study participation. Patients’ data was collected via e-CRF on the Web. Results: In total, 407 patients were enrolled (median age: 56 years, range: 20–86 years) between July 2010 and September 2019 from twenties hospitals of the Consortium for Improving Survival of Lymphoma (CISL). Male-to-female ratio was about 1.2 to 1 (219 vs. 188). Nodal MZLs were observed in 48 patients (11.8%). Almost of registered MZL patients was MZL of MALT type 359 (88.2%). The most common site of involvement was orbit and ocular adnexa (29.7%) followed by stomach (17%), multiple MALT sites involved (15.7%), and lung (5.4%). Ninety-four percent (384) of the patients initially presented with Ann Arbor stage I/II. BM involvement was detected in 7.3% (28 of 384). Bulky mass and B symptom was observed in only 3 patients, respectively. 71% of the patients (290 of 407) and 36 patients (8.8%) were categorized as the low and low-intermediate risk group according to the IPI, respectively. Initial treatment was conducted by Patients’ disease status; ten percentage of patients were observed without treatment. Chemotherapy alone 106 (26%), RT alone 80 (19.7%), Surgery + Chemotherapy 46 (11.3%), H. pylori eradication 35 (8.6%), Surgery alone 26 (6.4%). 5 years PFS and OS duration were 89.4% (32 events) and 97.3 (11 events). Eleven cases of hepatitis reactivation were observed during treatment. Conclusion: This is a first large scale prospective MZL cohort study in Korea. The results showed that the characteristics of MZL that survives for a long time and causes frequent recurrence were well represented. However, for accurate characteristic analysis, it is necessary to collect continuous survival-related data for the next five years or more. This study will replacing 207 retrospective studies published in 2004 and can be used as basic data to determine survival changes after Rituximab is used (ClinicalTrials.gov ID: NCT02732236). The research was funded by: The research was funded by JW pharmaceutical. Keyword: indolent non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract." @default.
• W4380079314 created "2023-06-10" @default.
• W4380079314 creator A5004789637 @default.
• W4380079314 creator A5012175622 @default.
• W4380079314 creator A5014535862 @default.
• W4380079314 creator A5014597278 @default.
• W4380079314 creator A5014636746 @default.
• W4380079314 creator A5022379369 @default.
• W4380079314 creator A5028474890 @default.
• W4380079314 creator A5032215557 @default.
• W4380079314 creator A5033232203 @default.
• W4380079314 creator A5036700956 @default.
• W4380079314 creator A5038124002 @default.
• W4380079314 creator A5038188064 @default.
• W4380079314 creator A5040549266 @default.
• W4380079314 creator A5043460941 @default.
• W4380079314 creator A5043917376 @default.
• W4380079314 creator A5044958787 @default.
• W4380079314 creator A5046987994 @default.
• W4380079314 creator A5051954293 @default.
• W4380079314 creator A5066039159 @default.
• W4380079314 creator A5069402999 @default.
• W4380079314 creator A5070668206 @default.
• W4380079314 creator A5075932421 @default.
• W4380079314 creator A5090760076 @default.
• W4380079314 date "2023-06-01" @default.
• W4380079314 modified "2023-10-18" @default.
• W4380079314 title "PROSPECTIVE KOREAN MARGINAL ZONE LYMPHOMAS COHORT STUDY: INITIAL DATA ANALYSIS OF 407 CASES" @default.
• W4380079314 doi "https://doi.org/10.1002/hon.3165_537" @default.
• W4380079314 hasPublicationYear "2023" @default.
• W4380079314 type Work @default.
• W4380079314 citedByCount "0" @default.
• W4380079314 crossrefType "journal-article" @default.
• W4380079314 hasAuthorship W4380079314A5004789637 @default.
• W4380079314 hasAuthorship W4380079314A5012175622 @default.
• W4380079314 hasAuthorship W4380079314A5014535862 @default.
• W4380079314 hasAuthorship W4380079314A5014597278 @default.
• W4380079314 hasAuthorship W4380079314A5014636746 @default.
• W4380079314 hasAuthorship W4380079314A5022379369 @default.
• W4380079314 hasAuthorship W4380079314A5028474890 @default.
• W4380079314 hasAuthorship W4380079314A5032215557 @default.
• W4380079314 hasAuthorship W4380079314A5033232203 @default.
• W4380079314 hasAuthorship W4380079314A5036700956 @default.
• W4380079314 hasAuthorship W4380079314A5038124002 @default.
• W4380079314 hasAuthorship W4380079314A5038188064 @default.
• W4380079314 hasAuthorship W4380079314A5040549266 @default.
• W4380079314 hasAuthorship W4380079314A5043460941 @default.
• W4380079314 hasAuthorship W4380079314A5043917376 @default.
• W4380079314 hasAuthorship W4380079314A5044958787 @default.
• W4380079314 hasAuthorship W4380079314A5046987994 @default.
• W4380079314 hasAuthorship W4380079314A5051954293 @default.
• W4380079314 hasAuthorship W4380079314A5066039159 @default.
• W4380079314 hasAuthorship W4380079314A5069402999 @default.
• W4380079314 hasAuthorship W4380079314A5070668206 @default.
• W4380079314 hasAuthorship W4380079314A5075932421 @default.
• W4380079314 hasAuthorship W4380079314A5090760076 @default.
• W4380079314 hasBestOaLocation W43800793141 @default.
• W4380079314 hasConcept C126322002 @default.
• W4380079314 hasConcept C141071460 @default.
• W4380079314 hasConcept C159654299 @default.
• W4380079314 hasConcept C188816634 @default.
• W4380079314 hasConcept C203014093 @default.
• W4380079314 hasConcept C2778453870 @default.
• W4380079314 hasConcept C2779338263 @default.
• W4380079314 hasConcept C2779526237 @default.
• W4380079314 hasConcept C2779921676 @default.
• W4380079314 hasConcept C71924100 @default.
• W4380079314 hasConcept C72563966 @default.
• W4380079314 hasConcept C90924648 @default.
• W4380079314 hasConceptScore W4380079314C126322002 @default.
• W4380079314 hasConceptScore W4380079314C141071460 @default.
• W4380079314 hasConceptScore W4380079314C159654299 @default.
• W4380079314 hasConceptScore W4380079314C188816634 @default.
• W4380079314 hasConceptScore W4380079314C203014093 @default.
• W4380079314 hasConceptScore W4380079314C2778453870 @default.
• W4380079314 hasConceptScore W4380079314C2779338263 @default.
• W4380079314 hasConceptScore W4380079314C2779526237 @default.
• W4380079314 hasConceptScore W4380079314C2779921676 @default.
• W4380079314 hasConceptScore W4380079314C71924100 @default.
• W4380079314 hasConceptScore W4380079314C72563966 @default.
• W4380079314 hasConceptScore W4380079314C90924648 @default.
• W4380079314 hasIssue "S2" @default.
• W4380079314 hasLocation W43800793141 @default.
• W4380079314 hasOpenAccess W4380079314 @default.
• W4380079314 hasPrimaryLocation W43800793141 @default.
• W4380079314 hasRelatedWork W1983816938 @default.
• W4380079314 hasRelatedWork W2022345153 @default.
• W4380079314 hasRelatedWork W2046077755 @default.
• W4380079314 hasRelatedWork W2046728107 @default.
• W4380079314 hasRelatedWork W2120034672 @default.
• W4380079314 hasRelatedWork W2325773848 @default.
• W4380079314 hasRelatedWork W2579733673 @default.
• W4380079314 hasRelatedWork W3123017657 @default.
• W4380079314 hasRelatedWork W4232822161 @default.
• W4380079314 hasRelatedWork W4383647438 @default.
• W4380079314 hasVolume "41" @default.
• W4380079314 isParatext "false" @default.
• W4380079314 isRetracted "false" @default.

• next